Low-Dose Triple Combination Pill Effective for Hypertension Control, finds study
A study published in the Journal of the American College of Cardiology found that a single-pill low-dose combination of amlodipine, losartan, and chlorthalidone is as effective as standard-dose amlodipine and both comparable and superior to losartan alone for short-term blood pressure reduction and control in mild to moderate hypertension
The studies, conducted
Across multiple centers in South Korea, this study evaluated a triple combination pill containing low doses of amlodipine, losartan potassium, and chlorthalidone. This formulation which is referred to as LDC-ALC, was tested against standard-dose monotherapies in adults with mild-to-moderate hypertension.
The first trial compared the combination pill with amlodipine alone. After 8 weeks of treatment, the results showed that LDC-ALC was just as effective in lowering systolic blood pressure. The patients in both groups experienced nearly identical reductions, with no meaningful statistical difference. Diastolic pressure improvements and overall blood pressure control rates were also comparable, which reinforced the combination pill’s ability to match a widely used first-line drug.
The second trial compared losartan alone to the triple combination pill, which not only met the criteria for noninferiority but also demonstrated superior performance. Patients taking LDC-ALC experienced greater reductions in systolic blood pressure, along with improved diastolic outcomes and higher rates of achieving target blood pressure levels.
Importantly, safety profiles across both studies remained consistent. Adverse events were similar between the combination therapy and monotherapy groups, and treatment discontinuation rates were extremely low. No serious drug-related complications were reported, suggesting that lowering individual drug doses while combining them does not compromise tolerability.
This “many-at-low-dose” strategy reflects a growing shift in how hypertension may be treated. Instead of increasing the dose of a single medication—which can raise the risk of side effects—clinicians may be able to use smaller amounts of multiple drugs to achieve the same or better results. Each component targets blood pressure through a different mechanism, potentially offering a more balanced and effective approach.
Experts say these findings are particularly significant because they come from rigorous phase III trials—the gold standard in clinical research. While earlier studies hinted at the promise of low-dose combination therapy, this is among the first high-quality evidence directly comparing such a regimen with standard treatments.
If adopted more widely, the single-pill triple therapy could simplify treatment plans, improve patient adherence, and expand options for first-line hypertension care. For millions living with elevated blood pressure, that could translate into better long-term outcomes and reduced risk of heart disease and stroke.
As research continues, the results position ultra-low-dose combination therapy as a serious contender alongside established monotherapy approaches—potentially reshaping the future of hypertension management.
Source:
Sung, K, Park, K, Kim, D. et al. Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension. JACC. null2026, 0 (0). https://doi.org/10.1016/j.jacc.2025.12.028
